Indee Labs, a biotechnology company developing a scalable, non-viral intracellular delivery system based on microfluidic vortex shedding (µVS), announced the United States Patent Office has issued U.S. Patent No. 10,501,716 covering a system for introducing exogenous material to cells with microfluidic vortex shedding. Similar patents have already been granted in Canada, Japan and Australia with additional jurisdictions pending. The Indee Labs group of companies is assigned and has exclusive rights to all patents, patent applications and proprietary information.

“We are excited to announce exclusive rights to our core technology, intracellular delivery with microfluidic vortex shedding, in multiple major jurisdictions including the United States,” stated Ryan Pawell, CEO of Indee Labs. “This patent is an important part of our growing portfolio and covers the system required for the intracellular delivery of exogenous materials to cells with µVS.”

The team at Indee Labs have made multiple advancements in the field of intracellular delivery. Key advantages of µVS include high yield of modified cells with rapid processing of µL- and mL-scale samples also resulting in negligible perturbation of the immune cell state. More detail is available in Nature Scientific Reports.

Source: Company Press Release